Cancers, Vol. 13, Pages 3902: Irreversible Electroporation and Nivolumab Combined with Intratumoral Administration of a Toll-like Receptor Ligand, as a Means of In Vivo Vaccination for Metastatic Pancreatic Ductal Adenocarcinoma (PANFIRE-III). A Phase-I Study Protocol

Cancers, Vol. 13, Pages 3902: Irreversible Electroporation and Nivolumab Combined with Intratumoral Administration of a Toll-like Receptor Ligand, as a Means of In Vivo Vaccination for Metastatic Pancreatic Ductal Adenocarcinoma (PANFIRE-III). A Phase-I Study Protocol Cancers doi: 10.3390/cancers13153902 Authors: Bart Geboers Florentine Timmer Alette Ruarus Johanna Pouw Evelien Schouten Joyce Bakker Robbert Puijk Sanne Nieuwenhuizen Madelon Dijkstra M. van den Tol Jan de Vries Daniela Oprea-Lager C. Menke-van der Houven van Oordt Hans van der Vliet Johanna Wilmink Hester Scheffer Tanja de Gruijl Martijn Group Irreversible electroporation (IRE) is a novel image-guided tumor ablation technique with the ability to generate a window for the establishment of systemic antitumor immunity. IRE transiently alters the tumor’s immunosuppressive microenvironment while simultaneously generating antigen release, thereby instigating an adaptive immune response. Combining IRE with immunotherapeutic drugs, i.e., electroimmunotherapy, has synergistic potential and might induce a durable antitumor response. The primary objective of this study is to assess the safety of the combination of IRE with IMO-2125 (a toll-like receptor 9 ligand) and/or nivolumab in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). In this randomized controlled phase I clinical trial, 18 patients with mPDAC pretreated with chemotherapy will be enrolled in one o...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Study Protocol Source Type: research